00:40 , Jan 12, 2017 |  BC Week In Review  |  Clinical News

99mTc-MIP-1404: Ph III ongoing

An IDMC recommended continuation of the open-label, North American Phase III proSPECT-AS trial evaluating a single 20 mCi IV injection of 99mTc-MIP-1404 based on an interim analysis. The trial has enrolled 190 of the planned...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Clinical News

99mTc-MIP-1404: Phase III started

Progenics began the open-label, North American Phase III proSPECT-AS trial to evaluate a single 20 mCi IV injection of 99mTc-MIP-1404 in about 450 patients with newly diagnosed low-grade prostate cancer who are candidates for active...
07:00 , Apr 27, 2015 |  BC Week In Review  |  Clinical News

99mTc-MIP-1404: Phase IIa started

Fujifilm began the open-label, Japanese Phase IIa trial to evaluate IV 99mTc-MIP-1404 followed by whole-body planar or SPECT/CT scan in about 15 newly diagnosed prostate cancer patients at high risk for metastatic disease. Fujifilm has...
01:46 , Feb 22, 2014 |  BC Extra  |  Financial News

Progenics raises $35 million in follow-on

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) raised $35 million through the sale of 7.6 million shares at $4.60 in a follow-on underwritten by Jefferies; Needham; and Brean Capital. Progenics proposed the offering late Thursday, when its share...
00:39 , Feb 21, 2014 |  BC Extra  |  Financial News

Progenics planning follow-on

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) proposed a follow-on late Thursday underwritten by Jefferies. Progenics has three unpartnered programs in Phase II testing, including PSMA ADC for metastatic castration-resistant prostate cancer (CRPC). The company reported data for...
08:00 , Feb 10, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/7 cls Fluidigm Corp. (NASDAQ:FLDM) Cowen Doug Schenkel Downgrade Market perform (from outperform)...
08:00 , Feb 3, 2014 |  BC Week In Review  |  Clinical News

99mTc-MIP-1404: Interim Phase II data

Interim data from 54 evaluable high-risk men with confirmed adenocarcinoma of the prostate who were scheduled for radical prostatectomy with extended pelvic lymph node dissection in an open-label, international Phase II trial showed that a...
03:00 , Jan 31, 2014 |  BC Extra  |  Clinical News

Progenics recovers some of its losses

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) was up $0.70 (16%) to $5.20 on Thursday, recovering some of the company's losses on Wednesday after an abstract from the American Society of Clinical Oncology Genitourinary Cancers Symposium revealed two...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

99mTc-MIP-1404: Phase I data

An open-label, U.S. Phase I trial in about 24 prostate cancer patients scheduled for prostatectomy and/or extended pelvic lymph node dissection showed that a single IV dose of 99mTc-MIP-1404 was well distributed and ready for...
07:00 , Oct 1, 2012 |  BC Week In Review  |  Clinical News

99mTc-MIP-1404: Phase II started

Molecular Insight began an open-label, international Phase II trial to evaluate a single IV dose of 99mTc-MIP-1404 followed by SPECT/CT scans 3-6 hours after injection in up to 120 high-risk prostate cancer patients scheduled for...